In the phase III ARISE trial, adjunctive xanomeline and trospium chloride (Cobenfy) were no better than placebo at improving ...

U.S. stock indexes rallied at midday Wednesday as President Donald Trump said he has "no intention" of firing Federal Reserve ...

Oncology experts discuss de-escalation strategies that can reduce toxicity, save a billion in healthcare costs, and make lung ...

Bristol-Myers Squibb is trading near all-time high dividend and free cash flow yields. Learn why BMY stock is a Buy.

The stock's rise snapped a four-day losing streak.

Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly ...

Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...

The Vatican announced that Pope Francis died from a stroke that was followed by a coma and irreversible cardiocirculatory ...

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

Bristol-Myers Squibb (NYSE: BMY) is scheduled to announce Q1 earnings results on Thursday, April 24th, before market open.

Fintel reports that on April 22, 2025, Piper Sandler initiated coverage of Bristol-Myers Squibb Company - Preferred Security ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report).